Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma

被引:56
|
作者
Vyth-Dreese, FA
Boot, H
Dellemijn, TAM
Majoor, DM
Oomen, LCJM
Laman, JD
Van Meurs, M
De Weger, RA
De Jong, D
机构
[1] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Div Gastroenterol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Div Pathol, NL-1066 CX Amsterdam, Netherlands
[4] Netherlands Canc Inst, Div Biophys, NL-1066 CX Amsterdam, Netherlands
[5] TNO, PG, Div Infect Dis & Immunol, Leiden, Netherlands
[6] Univ Utrecht Hosp, Dept Pathol, NL-3508 GA Utrecht, Netherlands
关键词
D O I
10.1046/j.1365-2567.1998.00550.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Costimulatory molecules are essential in cognate interactions between T and B lymphocytes. To study the prerequisites of functional interactions between malignant B cells and intermingled T cells in B-cell non-Hodgkin's lymphomas (B-NHL), we examined the expression of CD40, CD80 and CD86 and their ligands CD40 ligand (CD40L, CD154), CD28 and CTLA4 (CD152) using immunohistochemistry and confocal laser scanning microscopy. Almost all mucosa-associated lymphoid tissue (MALT) NHL were positive for CD40 and CD80 and in nine out of 14 cases were positive for CD86. The majority of follicle centre cell lymphomas (FCCL) expressed CD40, but were heterogeneous in their expression of CD80 and CD86. Most diffuse large cell lymphomas (DLCL) were CD80(+), but lacked expression of CD86. These patterns reflect the differences in phenotype of normal marginal-zone B cells (as counterparts of MALT NHL) and germinal centre cells (as counterparts of FCCL and DLCL). Counter-receptors on T cells were detectable in 13 of 14 MALT NHL, 12 of 16 FCCL but only occasionally in DLCL (three of 12 cases). A subgroup of FCCL was identified with T-cell expression of CD40L, CD28 and CTLA4 simultaneously with strong expression of CD40 and CD86 on the tumour B cells. These results indicate that MALT NHL and a subset of FCCL are most optimally equipped for functional interactions with T cells. This may be supported by the demonstration of cytokine production mainly in T cells - in MALT NHL [interleukin-2 (IL-2), interferon-gamma (IFN-gamma), IL-IO] and FCCL (IL-2, IFN-gamma) and to a lesser extent in DLCL.
引用
收藏
页码:580 / 586
页数:7
相关论文
共 50 条
  • [1] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
    Postema, EJ
    Boerman, OC
    Oyen, WJG
    Raemaekers, JMM
    Corstens, FHM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (11) : 1725 - 1735
  • [2] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
    Bodet-Milin, Caroline
    Ferrer, Ludovic
    Pallardy, Amandine
    Eugene, Thomas
    Rauscher, Aurore
    Faivre-Chauvet, Alain
    Barbet, Jacques
    Kraeber-Bodere, Francoise
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [3] Large B-cell non-Hodgkin lymphoma relapsing with meningeal localization
    Massa, Antonella
    Fozza, Claudio
    BLOOD, 2012, 119 (26) : 6185 - 6185
  • [4] Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study
    Gu, Yian
    Shore, Roy E.
    Arslan, Alan A.
    Koenig, Karen L.
    Liu, Mengling
    Ibrahim, Sherif
    Lokshin, Anna E.
    Zeleniuch-Jacquotte, Anne
    CANCER CAUSES & CONTROL, 2010, 21 (08) : 1323 - 1333
  • [5] Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study
    Yian Gu
    Roy E. Shore
    Alan A. Arslan
    Karen L. Koenig
    Mengling Liu
    Sherif Ibrahim
    Anna E. Lokshin
    Anne Zeleniuch-Jacquotte
    Cancer Causes & Control, 2010, 21 : 1323 - 1333
  • [6] B-cell non-Hodgkin's lymphoma of small lymphocytes
    Novosad, O.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S22
  • [7] Thymic B-cell non-Hodgkin's lymphoma in a child
    Azuma, E
    Nishihara, H
    Qi, J
    Nagai, M
    Hiratake, S
    Zhang, XL
    Komada, Y
    Hamazaki, M
    Sakurai, M
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 57 (01) : 48 - 50
  • [8] Emerging drugs in B-cell non-Hodgkin's lymphoma
    Kassam, Shireen
    Montoto, Silvia
    EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (02) : 323 - 343
  • [9] Use of bortezomib in B-cell non-Hodgkin's lymphoma
    Wang, Michael
    Zhou, Yuhong
    Zhang, Liong
    Nguyen, C. Ann
    Romaguera, Jorge
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (07) : 983 - 991
  • [10] Antibody therapy of non-Hodgkin's B-cell lymphoma
    Paul Chinn
    Gary Braslawsky
    Christine White
    Nabil Hanna
    Cancer Immunology, Immunotherapy, 2003, 52 : 257 - 280